MammaPrint has remained consistent and credible since introduction more than a decade ago

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

To the Editor:

One of the biggest questions that early-stage breast cancer patients face is whether they will benefit from chemotherapy treatment. Two large scale randomized clinical trials that implement genomic testing have positively addressed this question.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
William Audeh
Chief medical officer, Agendia
Table of Contents

YOU MAY BE INTERESTED IN

As NCI paylines drop to 4%, cancer centers are tapping into their institutional funds to provide “bridge funding,” typically in $50,000 to $100,000 increments, to enable investigators to keep their labs open until better times return—next year God willing.
William Audeh
Chief medical officer, Agendia

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login